贝达药业(300558) - 2022 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2022 was ¥409,380,718.51, a decrease of 28.09% year-over-year[5] - Net profit attributable to shareholders was ¥8,089,152.51, down 93.86% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥2,605,039.63, a decline of 97.98% year-over-year[5] - Total operating revenue for Q3 2022 was CNY 1,662,717,674.70, a decrease of 3.58% compared to CNY 1,724,419,673.98 in the same period last year[22] - The net profit for the third quarter of 2022 was approximately ¥88.79 million, a decrease of 74.1% compared to ¥342.69 million in the same period last year[23] - Operating profit for the quarter was ¥93.99 million, down 75.5% from ¥383.48 million in the previous year[23] - Total comprehensive income for the quarter was ¥139.73 million, down 66.7% from ¥419.24 million year-on-year[23] - The basic earnings per share for the quarter was ¥0.25, compared to ¥0.84 in the same period last year[23] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥209,680,381.29, a decrease of 54.46% compared to the previous year[9] - Cash flow from operating activities generated a net amount of ¥209.68 million, a decline of 54.5% compared to ¥460.46 million in the same period last year[24] - The company reported a decrease in cash and cash equivalents, ending the quarter with ¥679.13 million, down from ¥750.59 million at the end of the previous year[25] - As of September 30, 2022, the company's cash and cash equivalents amounted to 679,125,409.23 CNY, a decrease from 791,989,554.14 CNY at the beginning of the year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,318,664,699.62, reflecting a 16.70% increase from the end of the previous year[5] - The company's total assets reached CNY 7,318,664,699.62, an increase of 16.69% compared to CNY 6,271,432,076.94 in the previous year[21] - Total liabilities increased to CNY 2,386,817,609.95, a rise of 50.59% from CNY 1,585,642,380.84 in the previous year[21] - The company’s total liabilities included new short-term and long-term loans amounting to ¥380,348,251.50 and ¥604,500,000.00 respectively[8] Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,340, with the top 10 shareholders holding a combined 66.39% of shares[10] - Ningbo Kaiming Investment Management Partnership holds 19.22% of shares, amounting to 80,064,000 shares, while Zhejiang Jihe Venture Capital holds 13.04% with 54,324,000 shares[10] - The company continues to maintain a strong shareholder base with significant stakes held by institutional investors[10] - There were no changes in the number of preferred shareholders, indicating stability in this area[11] Research and Development - Research and development expenses for the first nine months of 2022 totaled ¥481,915,519.12, an increase of 31.84% year-over-year[9] - Research and development expenses increased to ¥481.92 million, up 31.8% from ¥365.53 million year-on-year[23] Sales and Inventory - Sales volume of the drug Kaimena increased by 26.54% year-over-year, while Beimeina's sales surged by 797.57%[7] - Total operating costs increased to CNY 1,609,425,586.40, up 17.61% from CNY 1,368,288,679.61 in the previous year[22] - Inventory as of Q3 2022 was CNY 371,966,757.74, an increase of 26.83% from CNY 293,321,689.12 in the previous year[20] Stock Options and Incentives - The total number of stock options exercised and registered during the reporting period was 182,664, with a cumulative total of 930,889 options exercised, representing 53.04% of the total available options[14] - The total number of stock options available for incentive objects was 2,126,464, with 241,489 options exercised during the reporting period, representing 56.14% of the total[14] - The 2018 (second phase) stock option incentive plan saw 930,889 stock options exercised, with 182,664 options exercised in the reporting period[13] - The company adjusted the grant price of the 2021 restricted stock incentive plan from 41.34 CNY/share to 41.09 CNY/share, granting a total of 2,802,100 restricted shares to 238 eligible participants[15] Management and Governance - The company’s management expenses increased by 109.40% to ¥429,057,814.32, largely due to stock incentive expenses[9] - The company’s independent directors approved the adjustments to the incentive plan, ensuring compliance with governance standards[15] - The company has disclosed various important matters in temporary reports, including announcements regarding shareholder pledge releases and extensions[18] Strategic Initiatives - The company has not reported any new product launches or technological developments in this quarter[12] - The company has not disclosed any plans for market expansion or mergers and acquisitions in this report[12] - The company continues to focus on market expansion and new product development as part of its strategic initiatives[18]